Cephalon seeking $300M note deal

CEPH, a developer of neurological and cancer therapeutics, filed

Read the full 90 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE